OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma

[1] Bondy ML(2008)Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium Cancer 113 1953-1968

[2] Scheurer ME(2014)Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology Pediatr Res 75 205-209

[3] Malmer B(2015)Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes Acta Neuropathol 130 815-827

[4] Barnholtz-Sloan JS(2016)The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol 131 803-820

[5] Davis FG(2019)ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma Commun Biol 2 156-335

[6] Il'Yasova D(2015)Inhibition of pediatric glioblastoma tumor growth by the anti-cancer agent OKN-007 in orthotopic mouse xenografts PLoS ONE 10 e0134276-806

[7] Schroeder KM(2019)OKN-007 increases temozolomide (TMZ) sensitivity and suppresses TMZ-resistant glioblastoma (GBM) tumor growth Transl Oncol 12 320-340

[8] Hoeman CM(2010)Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging J Magn Imaging 31 796-236

[9] Becher OJ(2013)Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007 Neuro Oncology 15 330-168

[10] Castel D(2013)The human sulfatase 2 inhibitor 2, 4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling Genes Chromosomes Cancer 52 225-461

[1] Bondy ML(2008)Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium Cancer 113 1953-1968

[2] Scheurer ME(2014)Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology Pediatr Res 75 205-209

[3] Malmer B(2015)Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes Acta Neuropathol 130 815-827

[4] Barnholtz-Sloan JS(2016)The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol 131 803-820

[5] Davis FG(2019)ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma Commun Biol 2 156-335

[6] Il'Yasova D(2015)Inhibition of pediatric glioblastoma tumor growth by the anti-cancer agent OKN-007 in orthotopic mouse xenografts PLoS ONE 10 e0134276-806

[7] Schroeder KM(2019)OKN-007 increases temozolomide (TMZ) sensitivity and suppresses TMZ-resistant glioblastoma (GBM) tumor growth Transl Oncol 12 320-340

[8] Hoeman CM(2010)Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging J Magn Imaging 31 796-236

[9] Becher OJ(2013)Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007 Neuro Oncology 15 330-168

[10] Castel D(2013)The human sulfatase 2 inhibitor 2, 4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling Genes Chromosomes Cancer 52 225-461